abrdn plc Invests $17.48 Million in Ascendis Pharma A/S (NASDAQ:ASND)

abrdn plc bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 138,791 shares of the biotechnology company’s stock, valued at approximately $17,481,000. abrdn plc owned about 0.24% of Ascendis Pharma A/S as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ASND. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 1.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company’s stock worth $1,762,000 after acquiring an additional 186 shares during the last quarter. Signaturefd LLC lifted its holdings in Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 193 shares during the last quarter. Values First Advisors Inc. grew its position in Ascendis Pharma A/S by 3.2% in the third quarter. Values First Advisors Inc. now owns 10,235 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 314 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in Ascendis Pharma A/S by 7.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 6,238 shares of the biotechnology company’s stock worth $584,000 after acquiring an additional 448 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Ascendis Pharma A/S by 2.9% in the third quarter. PNC Financial Services Group Inc. now owns 16,225 shares of the biotechnology company’s stock valued at $1,519,000 after purchasing an additional 457 shares during the period.

Ascendis Pharma A/S Trading Down 1.1 %

NASDAQ:ASND opened at $143.18 on Thursday. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00. The firm has a market cap of $8.34 billion, a PE ratio of -15.48 and a beta of 0.50. The stock has a fifty day moving average price of $149.15 and a 200 day moving average price of $125.48.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The business had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Equities analysts forecast that Ascendis Pharma A/S will post -4.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ASND. Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, April 18th. Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Wedbush upped their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $116.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.25.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.